12 research outputs found
Construction of a Shuttle Vector Using an Endogenous Plasmid From the Cyanobacterium Synechocystis sp. PCC6803
Comparison of microarray and qRT-PCR-based quantification of transcripts in a diurnal rhythm.
<p>Changes in organelle (chloroplast and mitochondrial) transcript levels between time points L2 and D2 in a wild-type strain of <i>C. reinhardtii</i> (CC-124) were determined by microarray and by qRT-PCR. The resulting fold-changes correlate with an R<sup>2</sup> value of 0.66. It is lower than 1.0, mainly because the microarray produces less accurate results for lowly expressed genes. All data points represent the average of three independent experiments.</p
Image_1_Construction of a Shuttle Vector Using an Endogenous Plasmid From the Cyanobacterium Synechocystis sp. PCC6803.PDF
<p>To advance synthetic biology in the photosynthetic cyanobacterium Synechocystis sp. PCC6803 (Syn6803), we constructed a shuttle vector with some versatile features. This shuttle vector, pSCB-YFP, consists of a putative replicon identified on the plasmid pCC5.2, the origin of replication of pMB1 from E. coli, as well as the YFP reporter gene and a spectinomycin/streptomycin resistance cassette. pSCB-YFP is stably maintained in Syn6803M (a motile strain that lacks the endogenous pCC5.2) and expresses YFP. In addition, we engineered a fragment into pSCB-YFP that has multiple cloning sites and other features such that this plasmid can also be used as an expression vector (pSCBe). The shuttle vector pSCB-YFP can be stably maintained for at least 50 generations without antibiotic selection. It is a high copy number plasmid and can stably co-exist with the RSF1010-based pPMQAK1-GFP.</p
k-means clustering of diurnal qRT-PCR data for chloroplast transcripts (left) and a subset of nuclear transcripts (right).
<p>The averaged data for six biological replicates were grouped into three clusters with the Pearson correlation as the distance metric. Gene profiles are colored according to the gene product’s function. Green: photosynthesis-related genes, blue: ribosome-related genes, red: plastid-encoded RNA polymerase genes, grey: miscellaneous genes. Clustering and visualization by Multiexperiment Viewer <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0108760#pone.0108760-Saeed1" target="_blank">[38]</a>.</p
Confirmation of the diurnal expression patterns observed in the pRT-PCR experiments by northern blot analyses.
<p>To avoid variation from RNA loading, each membrane was hybridized and stripped multiple times. The order of probing corresponds to the vertical order of the images (and the increasing signal intensity known to be obtained with the different probes). The ethidium bromide fluorescence (EtBr) remaining on the membrane after blotting is shown as a loading control.</p
Diurnal transcriptomics on bioreactor cultures of <i>Chlamydomonas</i>.
<p>The effect of 12 h light/12 h dark cycles on organelle (and selected nuclear) transcripts was analyzed by qRT-PCR. <i>C. reinhardtii</i> cells were grown in six independent bioreactor runs (run numbers 1, 2, 3, 15, 16, 20) and harvested at the time points indicated. Data obtained for plastome transcripts is shown in the upper portion of the heatmap, chondriome transcripts in the central region, and nuclear transcripts in the lower region. Within each genome, transcripts are listed alphabetically. Data are normalized to housekeeping transcripts and then to the average across all samples for that gene. Red boxes indicate up-regulation, green boxes: down-regulation, grey boxes: no data. Visualization by Multiexperiment Viewer <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0108760#pone.0108760-Saeed1" target="_blank">[38]</a>.</p
Behavior of functionally related chloroplast transcripts in diurnal conditions.
<p>The average peak time of all transcripts belonging to the three functional classes (red: plastid-encoded RNA polymerase genes, PEP; blue: ribosome-related genes; green: photosynthesis-related genes) is shown for each bioreactor experiment. The intensity of the circle represents the number of transcripts peaking at the time, and the black x represents the average of all transcripts. The yellow bar represents the 12 h light period, flanked by dark periods (grey bars).</p
Key bioreactor parameters from a representative bioreactor run (R2) in diurnal conditions.
<p>Turbidity (navy blue) slightly decreased during the dark period and increased during the light. The rapid peak after dusk and rapid drop after dawn are technical artefacts of the turbidimeter. The peaks in the weight graph correspond to the sampling times, when the fermenter was disturbed. Dissolved oxygen concentration increases from ca. 80% to ca. 150% very rapidly in the light. The pH of the culture is controlled by titration of acid or base, temperature is controlled by dynamic cooling to maintain reasonably stable values for these parameters. Samples were taken every 4 h, these points are indicated and also visible as peaks in the weight data (purple). Yellow bars represents the 12 h light period (L), flanked by dark periods (D; grey bars).</p
P633: UPDATED SAFETY AND EFFICACY RESULTS OF ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES WHO ARE INTOLERANT OF IBRUTINIB AND/OR ACALABRUTINIB
Recommended from our members
Zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma : interim analysis of a randomized phase III trial
PurposeZanubrutinib is a potent, irreversible next-generation Bruton tyrosine kinase (BTK) inhibitor designed to maximize BTK occupancy and minimize off-target kinase inhibition. We hypothesized that complete/sustained BTK occupancy may improve efficacy outcomes and increased BTK specificity may minimize off-target inhibition-related toxicities.Patients and methodsALPINE (ClinicalTrials.gov identifier: NCT03734016) is a global, randomized, open-label phase III study of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. The primary end point was investigator-assessed overall response rate (ORR). The preplanned interim analysis was scheduled approximately 12 months after the first 415 patients were enrolled.ResultsBetween November 1, 2018, and December 14, 2020, 652 patients were enrolled. We present the interim analysis of the first 415 enrolled patients randomly assigned to receive zanubrutinib (n = 207) or ibrutinib (n = 208). At 15 months of median follow-up, ORR (partial or complete response) was significantly higher with zanubrutinib (78.3%; 95% CI, 72.0 to 83.7) versus ibrutinib (62.5%; 95% CI, 55.5 to 69.1; two-sided P < .001). ORR was higher with zanubrutinib versus ibrutinib in subgroups with del(17p)/TP53 mutations (80.5% v 50.0%) and del(11q) (83.6% v 69.1%); 12-month progression-free survival in all patients was higher with zanubrutinib (94.9%) versus ibrutinib (84.0%; hazard ratio, 0.40; 95% CI, 0.23 to 0.69). Atrial fibrillation rate was significantly lower with zanubrutinib versus ibrutinib (2.5% v 10.1%; two-sided P = .001). Rates of cardiac events, major hemorrhages, and adverse events leading to treatment discontinuation/death were lower with zanubrutinib.ConclusionZanubrutinib had a significantly higher ORR, lower atrial fibrillation rate, and improved progression-free survival and overall cardiac safety profile versus ibrutinib. These data support improved efficacy/safety outcomes with selective BTK inhibition